SG11202109982YA - Drug and method for treating or preventing diabetes complications using same drug - Google Patents
Drug and method for treating or preventing diabetes complications using same drugInfo
- Publication number
- SG11202109982YA SG11202109982YA SG11202109982YA SG11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA
- Authority
- SG
- Singapore
- Prior art keywords
- group
- smtp
- formula
- week
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 | ||
| PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109982YA true SG11202109982YA (en) | 2021-10-28 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109982Y SG11202109982YA (en) | 2019-03-12 | 2020-03-12 | Drug and method for treating or preventing diabetes complications using same drug |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220218664A1 (https=) |
| EP (1) | EP3939659A4 (https=) |
| JP (1) | JPWO2020184691A1 (https=) |
| KR (1) | KR20220009371A (https=) |
| CN (1) | CN114126711A (https=) |
| AU (1) | AU2020238177A1 (https=) |
| BR (1) | BR112021018084A8 (https=) |
| CA (1) | CA3133204A1 (https=) |
| CL (1) | CL2021002373A1 (https=) |
| EA (1) | EA202192483A1 (https=) |
| IL (1) | IL286289A (https=) |
| MX (1) | MX2021011007A (https=) |
| PE (1) | PE20220333A1 (https=) |
| SG (1) | SG11202109982YA (https=) |
| WO (1) | WO2020184691A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| WO2022171151A1 (zh) * | 2021-02-10 | 2022-08-18 | 上海森辉医药有限公司 | 一种smtp-7衍生物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP4313049B2 (ja) * | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| US20090270476A1 (en) | 2005-10-06 | 2009-10-29 | Keiji Hasumi | Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof |
| EP2000540B1 (en) | 2006-03-27 | 2014-05-14 | Tokyo University of Agriculture and Technology Tlo Co., Ltd. | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| WO2011004620A1 (ja) * | 2009-07-06 | 2011-01-13 | 国立大学法人東京農工大学 | 細胞保護剤 |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| JP5952257B2 (ja) * | 2011-02-24 | 2016-07-13 | 株式会社ティムス | 可溶性エポキシドハイドロラーゼ阻害剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko not_active Withdrawn
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt not_active Application Discontinuation
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en not_active Abandoned
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja not_active Ceased
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020184691A1 (https=) | 2020-09-17 |
| EP3939659A4 (en) | 2022-12-21 |
| WO2020184691A1 (ja) | 2020-09-17 |
| KR20220009371A (ko) | 2022-01-24 |
| EA202192483A1 (ru) | 2021-12-24 |
| MX2021011007A (es) | 2022-03-11 |
| CA3133204A1 (en) | 2020-09-17 |
| IL286289A (en) | 2021-10-31 |
| US20220218664A1 (en) | 2022-07-14 |
| PE20220333A1 (es) | 2022-03-14 |
| CN114126711A (zh) | 2022-03-01 |
| BR112021018084A2 (https=) | 2021-12-21 |
| BR112021018084A8 (pt) | 2022-10-04 |
| EP3939659A1 (en) | 2022-01-19 |
| CL2021002373A1 (es) | 2022-06-17 |
| AU2020238177A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10688154B2 (en) | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists | |
| Eto et al. | Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression | |
| WO2013070879A1 (en) | Methods for treating spinal cord injury with lpa receptor antagonists | |
| Jensen et al. | Effect of insulin‐induced hypoglycaemia on the peripheral nervous system: focus on adaptive mechanisms, pathogenesis and histopathological changes | |
| Powell et al. | Gene therapy mediated seizure suppression in genetic generalised epilepsy: neuropeptide Y overexpression in a rat model | |
| SG11202109982YA (en) | Drug and method for treating or preventing diabetes complications using same drug | |
| KR20180071030A (ko) | 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물 | |
| US12453718B2 (en) | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | |
| Tan et al. | TGF‐β/Alk5 signaling prevents osteoarthritis initiation via regulating the senescence of articular cartilage stem cells | |
| AU2008210237B2 (en) | Use of catecholamines and related compounds as anti-angiogenic agents | |
| KR101752961B1 (ko) | 인테그린 알파3 베타1 저해제를 유효량 포함하는 당뇨병성 망막병증 치료용 조성물 및 치료용 조성물 탐색 방법 | |
| US20110130336A1 (en) | Method of treating ischemic injury using apoaequorin | |
| RS51481B (sr) | Lečenje amiotrofične lateralne skleroze | |
| WO2009103160A1 (en) | Treatment and prevention of dry age-related macular degeneration by activating cd36 | |
| Li et al. | AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways | |
| US20200323797A1 (en) | Treatment of Obesity-related Conditions | |
| HK40102111A (en) | Drug for treatment or prevention of cerebral hemorrhage, and method for treatment or prevention of cerebral hemorrhage using said drug | |
| AU2015271605B2 (en) | Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition | |
| RU2014141792A (ru) | Применение для лечения и профилактики атеросклероза белково-пептидного комплекса (далее-БПК), полученного из эмбриональной нервной ткани или из быстрозамороженного эмбрионального мозга сельскохозяйственных копытных животных, влияющего на обратный транспорт холестерина из сосудистой стенки и профиль активации моноцитов у пациентов с выраженным атеросклерозом магистральных сосудов или с предрасположенностью к сердечно-сосудистым заболеваниям и способ профилактики и лечения пациентов с атеросклерозом артериальных сосудов и с заболеваниями, вызванными атеросклерозом магистральных и периферических сосудов головного мозга, сердца, сосудов нижних конечностей и аорты (два варианта) | |
| JP5727167B2 (ja) | Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法 | |
| CA3179133A1 (en) | Methods and compositions for treating stroke | |
| WO2022113371A1 (ja) | 脳出血を治療又は予防するための薬剤及び該薬剤を用いて脳出血を治療又は予防する方法 | |
| Lenis | Cell-Autonomous Retinal Pigment Epithelium Dysfunction in Stargardt Disease |